Amgen wins appeal in US patent case over generic psoriasis drugs
Reuters
Published Apr 19, 2023 01:08PM ET
Updated Apr 19, 2023 01:21PM ET
By Blake Brittain
(Reuters) - Amgen Inc (NASDAQ:AMGN) convinced a U.S. appeals court on Wednesday to uphold patents that barred generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis' Sandoz Inc.
The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.
The ruling blocks proposed Otezla generics until 2028. The Federal Circuit also upheld a decision to invalidate one of Amgen's patents that Sandoz said would have barred its generics until 2034.
A spokesperson for Sandoz said Wednesday that the company was pleased with the decision allowing for Otezla generics in 2028 instead of 2034.
Representatives for Amgen and Zydus did not immediately respond to requests for comment.
Thousand Oaks, California-based Amgen sold over $2.2 billion worth of Otezla worldwide last year, according to a company filing with the U.S. Securities and Exchange Commission.
Amgen bought Otezla from Celgene Corp (NASDAQ:CELG) in 2019 for $13.4 billion. Celgene sued several drugmakers over their proposed Otezla generics starting in 2018, and 17 of the 19 lawsuits have been settled since.
U.S. District Judge Michael Shipp said in 2021 that Switzerland-based Sandoz and India-based Zydus' generics would infringe three Amgen patents.
Zydus and Sandoz appealed the decision that two of the infringed patents were valid. The Federal Circuit on Wednesday affirmed the ruling.
The court also affirmed that Amgen's patent that would have expired in 2034 was invalid over Amgen's cross-appeal.
The case is Amgen Inc v. Sandoz Inc, U.S. Court of Appeals for the Federal Circuit, Nos. 22-1147 and 22-1149.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.